CAR-T Cell Therapy Targets

CAR T-cell therapy is a type of immunotherapy called adoptive cell therapy: collecting and using patients’ own immune cells to treat their cancer. Using this approach, the T-cells are taken from the patient’s body and genetically engineered them to express a chimeric receptor (CAR) which recognizes a specific tumor-associated antigen. As a result, the CAR-expressing T cells, when reintroduced into the patient's system, will target and eliminate that specific tumor antigen expressing cells. CAR T cells are produced by transducing a genetically engineered CAR fusion protein by means of a retrovirus or lentivirus into autologous T cells. BioVision offers an extensive collection of recombinant proteins to support CAR-T therapy research.


Features & Benefits

Source: Expressed in HEK293 cells
High Purity: > 95% by SDS-PAGE
High Activity: validated in ELISA and other biological assays
Available for different species